A First-in-Human Study to Evaluate the Safety and Anti-cancer Activity of the product FS222, which is an Antibody medication, in Subjects with Advanced Malignancies

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-514010-12-00

Acronym

FS222-19101

Enrollment

323

Registered

2024-06-17

Start date

2020-12-03

Completion date

Unknown

Last updated

2025-04-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Malignancies

None listed

Sex/Gender

All

Age

18 Years to No maximum

Germany, Netherlands, Poland, Romania, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026